As Doenças Congênitas da Glicosilação (CDG) formam um grupo de erros inatos do metabolismo que está sendo cada vez mais reconhecido. Elas são caracterizadas por um problema na atividade das enzimas que participam da glicosilação – um processo em que proteínas e outras moléculas grandes são modificadas pela adição e alteração de pequenas cadeias de açúcar. Essas doenças abrangem uma grande variedade de manifestações e afetam diversas partes do corpo, como o sistema nervoso central, a função dos músculos, o sistema imunológico, o sistema endócrino e a coagulação (formação de coágulos). As muitas doenças que fazem parte desse grupo são subdivididas, de acordo com o tipo específico de processo de glicosilação que é afetado. As categorias incluem: problemas na N-glicosilação de proteínas, problemas na O-glicosilação de proteínas, problemas em múltiplos tipos de glicosilação e problemas na glicosilação de glicosfingolipídios e âncoras de glicosilfosfatidilinositol.
Introdução
O que você precisa saber de cara
ALG1-congenital disorder of glycosylation (ALG1-CDG, também conhecido como congenital disorder of glycosylation tipo Ik) é um distúrbio hereditário com sinais e sintomas variados que normalmente se desenvolvem durante a infância e podem afetar vários sistemas do corpo.
Pessoas com ALG1-CDG frequentemente apresentam deficiência intelectual, desenvolvimento atrasado e tônus muscular fraco (hipotonia). Muitas pessoas com a condição desenvolvem convulsões que podem ser difíceis de tratar. Pessoas com ALG1-CDG também podem ter problemas de movimento, como tremor (agitação rítmica involuntária) ou dificuldades de movimento e equilíbrio (ataxia).
Pessoas com ALG1-CDG frequentemente têm problemas de coagulação sanguínea, o que pode levar a coagulação anormal ou episódios de sangramento. Além disso, pessoas com a condição podem produzir níveis anormalmente baixos de proteínas chamadas anticorpos (ou imunoglobulinas), particularmente imunoglobulina G (IgG). Os anticorpos ajudam a proteger o corpo contra infecções por partículas e germes estranhos. Uma redução nos anticorpos pode dificultar que as pessoas com a condição combatam infecções.
Algumas pessoas com ALG1-CDG apresentam anomalias físicas, como tamanho de cabeça pequeno (microcefalia); características faciais incomuns; deformidades articulares chamadas contraturas; dedos das mãos e dos pés longos e finos (aracnodactilia); ou almofadas incomumente carnudas nas pontas dos dedos das mãos e dos pés. Problemas oculares que podem ocorrer em pessoas com esta condição incluem olhos que não apontam na mesma direção (estrabismo) ou movimentos oculares involuntários (nistagmo). Raramente, as pessoas com a condição desenvolvem perda de visão.
Anomalias menos comuns que ocorrem em pessoas com ALG1-CDG incluem problemas respiratórios, sensação reduzida nos braços e pernas (neuropatia periférica), inchaço (edema) e dificuldades gastrointestinais.
Os sinais e sintomas de ALG1-CDG são frequentemente graves, com as pessoas com a condição sobrevivendo apenas até a infância ou a primeira infância. No entanto, algumas pessoas com esta condição são menos afetadas e sobrevivem até a idade adulta.
Fonte: MedlinePlus Genetics (NLM/NIH), traduzidoAs Doenças Congênitas da Glicosilação (CDG) formam um grupo de erros inatos do metabolismo que está sendo cada vez mais reconhecido. Elas são caracterizadas por um problema na atividade das enzimas que participam da glicosilação – um processo em que proteínas e outras moléculas grandes são modificadas pela adição e alteração de pequenas cadeias de açúcar. Essas doenças abrangem uma grande variedade de manifestações e afetam diversas partes do corpo, como o sistema nervoso central, a função dos músculos, o sistema imunológico, o sistema endócrino e a coagulação (formação de coágulos). As muitas doenças que fazem parte desse grupo são subdivididas, de acordo com o tipo específico de processo de glicosilação que é afetado. As categorias incluem: problemas na N-glicosilação de proteínas, problemas na O-glicosilação de proteínas, problemas em múltiplos tipos de glicosilação e problemas na glicosilação de glicosfingolipídios e âncoras de glicosilfosfatidilinositol.
O que está sendo pesquisado
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 680 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 1686 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
69 genes identificados com associação a esta condição. Padrão de herança: Autosomal recessive, X-linked recessive.
Curadoria gene-doença
fontes oficiaisCongenital disorder of glycosylation 1T
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Congenital disorder of glycosylation with defective fucosylation 2
A form of congenital disorder of glycosylation, a genetically heterogeneous group of multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. CDGF2 is an autosomal recessive disorder, apparent from birth, characterized by hypotonia, poor feeding, severely impaired intellectual and psychomotor development, seizures with epileptic encephalopathy, visual impairment and other ocular features, respiratory difficulty with frequent infections, as well as contractures. Brain imaging shows cerebellar and brainstem atrophy, hypoplasia or agenesis of the corpus callosum, and white matter abnormalities including periventricular leukomalacia.
Congenital disorder of glycosylation 1DD
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG1DD transmission pattern is consistent with pseudoautosomal recessive inheritance.
Congenital disorder of glycosylation with defective fucosylation 1
A form of congenital disorder of glycosylation, a genetically heterogeneous group of multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDGF1 is an autosomal recessive disorder, apparent from birth, characterized by poor growth, failure to thrive, hypotonia, skeletal anomalies, and delayed psychomotor development with intellectual disability.
Congenital disorder of glycosylation 1F
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Hereditary multiple exostoses 2
EXT is a genetically heterogeneous bone disorder caused by genes segregating on human chromosomes 8, 11, and 19 and designated EXT1, EXT2 and EXT3 respectively. EXT is a dominantly inherited skeletal disorder primarily affecting endochondral bone during growth. The disease is characterized by formation of numerous cartilage-capped, benign bone tumors (osteocartilaginous exostoses or osteochondromas) that are often accompanied by skeletal deformities and short stature. In a small percentage of cases exostoses have exhibited malignant transformation resulting in an osteosarcoma or chondrosarcoma. Osteochondromas development can also occur as a sporadic event.
Congenital disorder of glycosylation 1D
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3
An autosomal recessive disorder characterized by congenital muscular dystrophy, ocular abnormalities, cobblestone lissencephaly, and cerebellar and pontine hypoplasia. Patients present severe congenital myopia, congenital glaucoma, pallor of the optic disks, retinal hypoplasia, intellectual disability, hydrocephalus, abnormal electroencephalograms, generalized muscle weakness and myoclonic jerks. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.
Congenital disorder of glycosylation 1P
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Congenital disorder of glycosylation 2O
A form of congenital disorder of glycosylation, a genetically heterogeneous group of autosomal recessive, multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG2O is characterized by hepatosplenomegaly, liver failure, hypotonia, and psychomotor disability.
Sialuria
In sialuria, free sialic acid accumulates in the cytoplasm and gram quantities of neuraminic acid are secreted in the urine. The metabolic defect involves lack of feedback inhibition of UDP-GlcNAc 2-epimerase by CMP-Neu5Ac, resulting in constitutive overproduction of free Neu5Ac. Clinical features include variable degrees of developmental delay, coarse facial features and hepatomegaly. Sialuria inheritance is autosomal dominant.
Ehlers-Danlos syndrome, spondylodysplastic type, 2
A form of Ehlers-Danlos syndrome, a group of connective tissue disorders characterized by skin hyperextensibility, articular hypermobility, and tissue fragility. EDSSPD2 is an autosomal recessive form characterized by an aged appearance, developmental delay, short stature, craniofacial disproportion, generalized osteopenia, defective wound healing, hypermobile joints, hypotonic muscles, and loose but elastic skin.
Congenital disorder of glycosylation 1G
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Congenital disorder of glycosylation 2D
A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Dowling-Degos disease 4
A form of Dowling-Degos disease, a genodermatosis manifesting with postpubertal reticulate hyperpigmentation that is progressive and disfiguring, and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails. DDD4 is characterized by prominent involvement of non-flexural skin areas.
Congenital disorder of glycosylation 2G
A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Clinical features of CDG2G include failure to thrive, generalized hypotonia, growth retardation and mild psychomotor retardation. CDG2G is biochemically characterized by a defect in O-glycosylation as well as N-glycosylation.
Congenital disorder of glycosylation 2J
A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Congenital disorder of glycosylation 1B
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG1B is clinically characterized by protein-losing enteropathy.
Congenital disorder of glycosylation 1J
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Congenital disorder of glycosylation 2V
A form of congenital disorder of glycosylation, a genetically heterogeneous group of multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG2V is an autosomal recessive form characterized by neurodevelopmental delay and variable facial dysmorphic features.
Multiple congenital anomalies-hypotonia-seizures syndrome 3
An autosomal recessive syndrome characterized by distinct facial features, intellectual disability, hypotonia and seizures, in combination with abnormal skeletal, endocrine, and ophthalmologic findings including impaired vision, as well as abnormal motility of the eyes.
Type IIb congenital disorder of glycosylation
Characterized by marked generalized hypotonia and hypomotility of the neonate, dysmorphic features, including a prominent occiput, short palpebral fissures, retrognathia, high arched palate, generalized edema, and hypoplastic genitalia. Symptoms of the infant included hepatomegaly, hypoventilation, feeding problems and seizures. The clinical course was progressive and the infant did not survive more than a few months.
Hyperphosphatasia with impaired intellectual development syndrome 6
An autosomal recessive, multisystem disorder characterized by severe developmental delay, dysmorphism, seizures, cataracts, and early death in some patients.
Congenital disorder of glycosylation 1K
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Congenital disorder of glycosylation 1U
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Some CDG1U patients have dystrophic changes seen on muscle biopsy and reduced O-mannosyl glycans on alpha-dystroglycan.
Congenital disorder of glycosylation 1Q
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B15
An autosomal recessive, congenital muscular disorder characterized by hyperCKemia, myopathic features observed on muscle biopsy, developmental delay, mildly impaired intellectual development with learning difficulties, epilepsy, and mild white matter abnormalities.
Peters-plus syndrome
An autosomal recessive disorder characterized by anterior eye-chamber abnormalities, disproportionate short stature, developmental delay, characteristic craniofacial features, cleft lip and/or palate.
Congenital disorder of glycosylation 2A
A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Muscular dystrophy-dystroglycanopathy limb-girdle C9
An autosomal recessive muscular dystrophy showing onset in early childhood, and associated with intellectual disability without structural brain anomalies.
Spondylocostal dysostosis 2, autosomal recessive
A condition of variable severity associated with vertebral and rib segmentation defects. The main skeletal malformations include fusion of vertebrae, hemivertebrae, fusion of certain ribs, and other rib malformations. Deformity of the chest and spine (severe scoliosis, kyphoscoliosis and lordosis) is a natural consequence of the malformation and leads to a dwarf-like appearance. As the thorax is small, infants frequently have respiratory insufficiency and repeated respiratory infections resulting in life-threatening complications in the first year of life.
Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B1
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with intellectual disability and mild structural brain abnormalities.
Myasthenic syndrome, congenital, 15
A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness.
Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A5
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.
Coloboma, congenital heart disease, ichthyosiform dermatosis, impaired intellectual development, and ear anomalies syndrome
An extremely rare autosomal recessive multisystem disorder clinically characterized by colobomas, congenital heart defects, migratory ichthyosiform dermatosis, intellectual disability, and ear anomalies including conductive hearing loss. Other clinical features include distinctive facial features, abnormal growth, genitourinary abnormalities, seizures, and feeding difficulties.
Congenital disorder of glycosylation 2I
A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Congenital disorder of glycosylation type 2I is characterized by mild neurological impairments.
Congenital disorder of glycosylation 1E
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Some CDG1E patients have features consistent with a dystroglycanopathy and congenital muscular dystrophy, including O-mannosylation defect, camptodactyly, elevated creatine kinase, motor delay and dystrophic changes on muscel biopsy.
Congenital disorder of glycosylation 1A
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. CDG1A is an autosomal recessive disorder characterized by a severe encephalopathy with axial hypotonia, abnormal eye movement, and pronounced psychomotor retardation, as well as peripheral neuropathy, cerebellar hypoplasia, and retinitis pigmentosa. Patients show a peculiar distribution of subcutaneous fat, nipple retraction, and hypogonadism.
Rafiq syndrome
An autosomal recessive disorder characterized by variably impaired intellectual and motor development, a characteristic facial dysmorphism, truncal obesity, and hypotonia. The facial dysmorphism comprises prominent eyebrows with lateral thinning, downward-slanting palpebral fissures, bulbous tip of the nose, large ears, and a thin upper lip. Behavioral problems, including overeating, verbal and physical aggression, have been reported in some cases. Serum transferrin isoelectric focusing shows a type 2 pattern.
Acne inversa, familial, 2, with or without Dowling-Degos disease
An autosomal dominant form of acne inversa, a chronic relapsing inflammatory disease of the hair follicles characterized by recurrent draining sinuses, painful skin abscesses, and disfiguring scars. Manifestations typically appear after puberty. Some ACNINV2 patients also exhibit reticulate hyperpigmentation consistent with Dowling-Degos disease.
Spondylocostal dysostosis 5
A rare condition of variable severity characterized by vertebral and costal anomalies. The main feature include dwarfism, vertebral fusion, hemivertebrae, posterior rib fusion, reduced rib number, and other rib malformations. SCDO5 inheritance can be autosomal dominant or recessive.
Spondylocostal dysostosis 4, autosomal recessive
A rare condition of variable severity characterized by vertebral and costal anomalies. The main feature include dwarfism, vertebral fusion, hemivertebrae, posterior rib fusion, reduced rib number, and other rib malformations.
Hyperphosphatasia with impaired intellectual development syndrome 4
An autosomal recessive neurologic disorder characterized by profound developmental delay, severe intellectual disability, no speech, psychomotor delay, postnatal microcephaly, and elevated serum alkaline phosphatase.
Epilepsy, progressive myoclonic 3, with or without intracellular inclusions
A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM3 is an autosomal recessive, severe, form with early onset. Multifocal myoclonic seizures begin between 16 and 24 months of age after normal initial development. Neurodegeneration and regression occur with seizure onset. Other features include intellectual disability, dysarthria, truncal ataxia, and loss of fine finger movements. EEG shows slow dysrhythmia, multifocal and occasionally generalized epileptiform discharges. In some patients, ultrastructural findings on skin biopsies identify intracellular accumulation of autofluorescent lipopigment storage material, consistent with neuronal ceroid lipofuscinosis.
Congenital disorder of glycosylation 1X
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Congenital disorder of glycosylation 1W, autosomal recessive
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Dowling-Degos disease 2
An autosomal dominant genodermatosis. Affected individuals develop a postpubertal reticulate hyperpigmentation that is progressive and disfiguring, and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails.
Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A2
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.
Ehlers-Danlos syndrome, musculocontractural type 2
A form of Ehlers-Danlos syndrome characterized by progressive multisystem manifestations, including joint dislocations and deformities, skin hyperextensibility, skin bruisability and fragility with recurrent large subcutaneous hematomas, cardiac valvular, respiratory, gastrointestinal, and ophthalmologic complications. Motor developmental delay is associated with muscle hypoplasia, muscle weakness, and an abnormal muscle fiber pattern in histology in adulthood.
Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A7
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.
Congenital disorder of glycosylation 1C
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A4
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.
Glycosylphosphatidylinositol biosynthesis defect 1
An autosomal recessive disorder characterized by portal vein thrombosis and portal hypertension, absence seizures, macrocephaly, splenomegaly, cytopenias and early-onset cerebral infarctions.
Congenital disorder of glycosylation 2E
A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Congenital disorder of glycosylation 1H
A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A8
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.
Spondylocostal dysostosis 6, autosomal recessive
A form of spondylocostal dysostosis, a condition of variable severity associated with vertebral and rib segmentation defects. The main skeletal malformations include fusion of vertebrae, hemivertebrae, fusion of certain ribs, and other rib malformations. Deformity of the chest and spine (severe scoliosis, kyphoscoliosis and lordosis) is a natural consequence of the malformation and leads to a dwarf-like appearance. As the thorax is small, infants frequently have respiratory insufficiency and repeated respiratory infections resulting in life-threatening complications in the first year of life.
Multiple joint dislocations, short stature, and craniofacial dysmorphism with or without congenital heart defects
An autosomal recessive disease characterized by dysmorphic facies, bilateral dislocations of the elbows, hips, and knees, clubfeet, and short stature, as well as cardiovascular defects.
Epidermolysis bullosa simplex 2A, generalized severe
A form of epidermolysis bullosa simplex, a group of skin fragility disorders characterized by skin blistering due to cleavage within the basal layer of keratinocytes, and erosions caused by minor mechanical trauma. There is a broad spectrum of clinical severity ranging from minor blistering on the feet, to subtypes with extracutaneous involvement and a lethal outcome. EBS2A is an autosomal dominant, severe form characterized by extensive intraepidermal blistering from the time of birth with herpetiform marginal spreading and central healing. Oral mucosal involvement, nail dystrophy, onychogryposis, formation of milia, and palmoplantar hyperkeratosis are common features.
Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A12
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.
Glycogen storage disease 1B
A metabolic disorder characterized by impairment of terminal steps of glycogenolysis and gluconeogenesis. Patients manifest a wide range of clinical symptoms and biochemical abnormalities, including hypoglycemia, severe hepatomegaly due to excessive accumulation of glycogen, kidney enlargement, growth retardation, lactic acidemia, hyperlipidemia, and hyperuricemia. Glycogen storage disease type 1B patients also present a tendency towards infections associated with neutropenia, relapsing aphthous gingivostomatitis, and inflammatory bowel disease.
Cowden syndrome 7
A form of Cowden syndrome, a hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid. CWS7 inheritance is autosomal dominant.
Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A14
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with brain anomalies, eye malformations, and profound intellectual disability. The disorder includes a severe form designated as Walker-Warburg syndrome and a less severe phenotype known as muscle-eye-brain disease. MDDGA14 features include increased muscle tone, microcephaly, cleft palate, feeding difficulties, severe muscle weakness, sensorineural hearing loss, cerebellar hypoplasia, ataxia, and retinal dysfunction.
Congenital disorder of glycosylation 2N
A form of congenital disorder of glycosylation, a genetically heterogeneous group of autosomal recessive, multisystem disorders caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Temtamy preaxial brachydactyly syndrome
A syndrome characterized by multiple congenital anomalies, intellectual disability, sensorineural deafness, talon cusps of upper central incisors, growth retardation, and bilateral symmetric digital anomalies mainly in the form of preaxial brachydactyly and hyperphalangism.
Congenital disorder of glycosylation 2L
A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Clinical features of CDG2L include neonatal intractable focal seizures, vomiting, loss of consciousness, intracranial bleeding due to vitamin K deficiency, and death in infancy.
Medicamentos e terapias
Mecanismo: Aldose reductase inhibitor
Mecanismo: Carbonic anhydrase XII inhibitor
Variantes genéticas (ClinVar)
280 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 3.561 variantes classificadas pelo ClinVar.
Vias biológicas (Reactome)
110 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Doença congênita da glicosilação
Centros de Referência SUS
24 centros habilitados pelo SUS para Doença congênita da glicosilação
Centros para Doença congênita da glicosilação
Detalhes dos centros
Hospital Universitário Prof. Edgard Santos (HUPES)
R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808
Serviço de Referência
Hospital Infantil Albert Sabin
R. Tertuliano Sales, 544 - Vila União, Fortaleza - CE, 60410-794 · CNES 2407876
Serviço de Referência
Hospital de Apoio de Brasília (HAB)
AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456
Serviço de Referência
Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)
Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207
Serviço de Referência
Hospital das Clínicas da UFG
Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424
Serviço de Referência
Hospital Universitário da UFJF
R. Catulo Breviglieri, Bairro - s/n - Santa Catarina, Juiz de Fora - MG, 36036-110 · CNES 2297442
Atenção Especializada
Hospital das Clínicas da UFMG
Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167
Serviço de Referência
Hospital Universitário Julio Müller (HUJM)
R. Luis Philippe Pereira Leite, s/n - Alvorada, Cuiabá - MT, 78048-902 · CNES 2726092
Atenção Especializada
Hospital Universitário João de Barros Barreto
R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878
Serviço de Referência
Hospital Universitário Lauro Wanderley (HULW)
R. Tabeliao Estanislau Eloy, 585 - Castelo Branco, João Pessoa - PB, 58050-585 · CNES 0002470
Atenção Especializada
Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)
R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647
Serviço de Referência
Hospital Pequeno Príncipe
R. Des. Motta, 1070 - Água Verde, Curitiba - PR, 80250-060 · CNES 3143805
Serviço de Referência
Hospital Universitário Regional de Maringá (HUM)
Av. Mandacaru, 1590 - Parque das Laranjeiras, Maringá - PR, 87083-240 · CNES 2216108
Atenção Especializada
Hospital de Clínicas da UFPR
R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980
Serviço de Referência
Hospital Universitário Pedro Ernesto (HUPE-UERJ)
Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221
Serviço de Referência
Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)
Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988
Serviço de Referência
Hospital São Lucas da PUCRS
Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928
Serviço de Referência
Hospital de Clínicas de Porto Alegre (HCPA)
Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601
Serviço de Referência
Hospital Universitário da UFSC (HU-UFSC)
R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356
Serviço de Referência
Hospital das Clínicas da FMUSP
R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485
Serviço de Referência
Hospital de Base de São José do Rio Preto
Av. Brg. Faria Lima, 5544 - Vila Sao Jose, São José do Rio Preto - SP, 15090-000 · CNES 2079798
Atenção Especializada
Hospital de Clínicas da UNICAMP
R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223
Serviço de Referência
Hospital de Clínicas de Ribeirão Preto (HCRP-USP)
R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187
Serviço de Referência
UNIFESP / Hospital São Paulo
R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689
Serviço de Referência
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Com ensaio aberto em 2 países. O ponto verde marca onde há vaga agora.
🟢 Recrutando agora
3 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
13 ensaios clínicos encontrados, 5 ativos.
Publicações mais relevantes
Extensive Hypoglycosylation of Serum N-Glycoproteins in SRD5A3 Deficiency.
Polyprenal reductase is an enzyme encoded by the SRD5A3 gene, which is involved in the synthesis of dolichol from polyprenol. Dolichol serves as a carrier for glycan precursors or monosaccharides in N-linked glycosylation. Pathogenic variants in SRD5A3 can result in a congenital disorder of glycosylation (CDG), SRD5A3-CDG, which is inherited in an autosomal recessive manner. Most plasma proteins are glycosylated and changes in the glycosylation of several glycoproteins are associated with pathological consequences. Despite the critical role of SRD5A3 in glycosylation, the impact of its deficiency on the glycosylation of serum proteins remains largely unexplored. In this study, we used tandem mass tag-based multiplexed quantitative approach to analyze serum N-glycoproteomics and proteomics in SRD5A3-CDG patients and controls. We quantified 2200 serum N-glycopeptides from 359 N-glycosites from 204 serum proteins. Extensive hypoglycosylation of serum proteins was observed in patients, with 245 of 291 altered glycopeptides decreased in SRD5A3-CDG. Altered glycopeptides included those derived from haptoglobin, plasma serine protease inhibitor, alpha-1-B glycoprotein, alpha-2-macroglobulin, and ceruloplasmin. Some of these proteins have previously been reported to be associated with liver dysfunction, anemia, and coagulopathy, which could underlie similar clinical features observed in SRD5A3-CDG patients. Overall, our study provides novel insights into alterations in the glycosylation status of specific serum proteins in SRD5A3-CDG. Some of these alterations could be further pursued to develop glycopeptide-based biomarkers as the current diagnosis of SRD5A3-CDG by screening assays remains challenging. In addition, knowledge of altered glycoproteins could enhance our understanding of the disease spectrum and potentially unveil additional therapeutic avenues.
GMPPB-CDG Results in Lysosomal Dysfunction and Acid Alpha-Glucosidase Deficiency.
GDP-mannose pyrophosphorylase B (GMPPB) deficiency is a congenital disorder of glycosylation due to pathogenic variants of the GMPPB gene. GMPPB catalyzes GDP-mannose synthesis, an early step in multiple glycosylation pathways, including N-glycosylation, O-mannosylation, C-mannosylation, and glycosylphosphatidylinositol-anchor formation. In fibroblasts (N = 3), myoblasts (N = 4) and in muscle biopsies (N = 4) from a total of 7 GMPPB-deficient patients we found evidence of glycogen accumulation, both in cytosol and in lysosome-like vesicles, presence of heterogeneous storage material, and expansion of the lysosomal compartment. Due to the excess of glycogen in cells and tissues, we investigated acid alpha-glucosidase (GAA) in cultured GMPPB fibroblasts. GAA activity was reduced in GMPPB cells, with an impaired protein maturation and lysosomal localization. Incubation of cells with human recombinant GAA (rhGAA), that is fully glycosylated, showed complete correction of GAA activity, normal processing and lysosomal trafficking, with complete clearance of glycogen storage. These results suggest a secondary impairment of specific lysosomal functions in GMPPB deficiency and add information on the complexity of the pathophysiology of this disorder.
Cerebral blood flow and benzodiazepine receptor distribution in a patient with ALG6-congenital disorder of glycosylation.
Unilateral Multicystic Dysplastic Kidney in a Fetus Associated With Parental Genetic and Environmental Risk Factors: A Case Report.
Multicystic dysplastic kidney (MCDK) is a congenital renal anomaly identified on prenatal ultrasound. They often arise sporadically and unilaterally. Our case involves an isolated unilateral MCDK in a fetus born to a mother with generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), and gastroesophageal reflux disease (GERD), with the father having chronic occupational lead exposure and a congenital disorder of glycosylation type 1A (PMM2-CDG). Our case highlights the multifactorial etiology of renal dysplasia and its potential role of glycosylation defects and environmental toxicity in abnormal kidney development. Contributions from genetic, environmental, and metabolic influences during nephrogenesis contribute to MCDK.
Neuro-Ophthalmic Presentation of Steroid 5a-Reductase Type 3 Congenital Disorder of Glycosylation: A Case of Monozygotic Twins.
We report a very rare autosomal recessive metabolic disorder in monozygotic twin sisters caused by the steroid 5a-reductase type 3 (SRD5A3) gene defect, a subtype of congenital disorder of glycosylation (CDG). SRD5A3 activity is required for N-glycosylation of proteins. This step is important for the protein to gain its function. The condition is characterized by severe neurodevelopmental delay, cerebellar atrophy or hypoplasia, ocular abnormalities, and ichthyotic skin changes. We describe 20-month-old female monozygotic twins born to non-consanguineous South Asian parents. Notably, both twins exhibited generalized tonic-clonic seizures starting in early infancy - a feature less commonly reported in SRD5A3-CDG. Physical examination of both children showed central hypotonia and bilateral horizontal nystagmus. Fundoscopy of the twins showed optic disc pallor suggestive of optic atrophy. Other features, such as ichthyosis and joint laxity, were absent. Crucially, despite prominent neurological symptoms, brain MRIs at 20 months were entirely normal, showing no evidence of cerebellar hypoplasia or atrophy typically associated with this condition. Whole-exome sequencing identified a homozygous nonsense mutation at exon 1 c.57G>A (p.Trp19Ter), in the SRD5A3 gene, classified as a pathogenic variant as per the American College of Medical Genetics and Genomics (ACMG), helping in establishing the diagnosis. SRD5A3-CDG should be one of the differentials in infants with unexplained seizures, hypotonia, and early ocular signs. This case highlights the phenotypic diversity of SRD5A3-CDG and demonstrates that structural brain anomalies may be absent in the early years of life. It underscores the importance of considering CDG as a differential in infants with unexplained hypotonia and ocular signs, even in the setting of normal neuroimaging.
Publicações recentes
Immunological Manifestations in GALE Deficiency: Extending the Spectrum Beyond Thrombocytopenia and Galactosemia.
Lipo-Glc-1,6-P(2): A Bioprecursor Prodrug for Phosphomannomutase-2 Congenital Disorder of Glycosylation.
🥈 ObservacionalEarly neonatal diagnosis of SSR4-related congenital disorder of glycosylation with severe congenital heart defects: a case report and systematic review.
A Homozygous Nonsense Variant in the Oligosaccharyltransferase Complex Gene, RPN1, Causes a Congenital Disorder of Glycosylation.
Expanded Clinical Spectrum of Autosomal-Dominant STT3A-CDG.
📚 EuropePMC325 artigos no totalmostrando 196
Unilateral Multicystic Dysplastic Kidney in a Fetus Associated With Parental Genetic and Environmental Risk Factors: A Case Report.
CureusNeuro-Ophthalmic Presentation of Steroid 5a-Reductase Type 3 Congenital Disorder of Glycosylation: A Case of Monozygotic Twins.
CureusSpecific Detection of Sialyltransferase ST3GAL3 Towards Lipid Acceptors by Liquid Chromatography Coupled with Tandem Mass Spectrometry Indicates Total Loss of Enzyme Activity in ST3GAL3 Pathogenic Variants.
BiomedicinesExtensive Hypoglycosylation of Serum N-Glycoproteins in SRD5A3 Deficiency.
Journal of inherited metabolic diseasePGM1 deficiency is linked to sarcomeric and mitochondrial dysfunction in patient-derived iPSC-cardiomyocytes.
Journal of translational medicineA founder variant in Tunisian PMM2-CDG patients: An integrated clinical, radiological, biochemical, and genetic study.
Molecular genetics and metabolismEarly Diagnosis and Targeted Therapy in SLC39A8-Congenital Disorder of Glycosylation: A Case Report From Bulgaria.
CureusClinical, biochemical and genetic characterization of an Egyptian patient with SRD5A3-congenital glycosylation disorder.
Ophthalmic geneticsRepurposing the HMG-CoA Reductase Inhibitor Atorvastatin for SRD5A3-CDG.
bioRxiv : the preprint server for biologyMulti-omics analysis reveals ER stress as a main feature in two endothelial cell models of N-linked congenital disorders of glycosylation.
Molecular genetics and metabolismGMPPB-CDG Results in Lysosomal Dysfunction and Acid Alpha-Glucosidase Deficiency.
Journal of inherited metabolic diseaseCerebral blood flow and benzodiazepine receptor distribution in a patient with ALG6-congenital disorder of glycosylation.
Pediatrics international : official journal of the Japan Pediatric SocietyPMM2-CDG and the Role of Liver Transplantation as a Long-Term Solution: A Case Report.
Pediatric transplantationDisorders of sex development associated with MPI and RSPH1 variants expand the phenotypic spectrum of CDG and PCD in Morocco.
Molecular biology reportsL-fucose supplementation in a patient with global hypofucosylation and a mono-allelic variant in SLC35C1: Clinical improvement and assessment of biomarkers.
Molecular genetics and metabolismProposed mechanism for Rft1-mediated scrambling of a dolichol-linked oligosaccharide.
bioRxiv : the preprint server for biologyDDOST-Congenital Disorder of Glycosylation: Defining the Clinical Spectrum and First Report of a Structural Variant.
American journal of medical genetics. Part AIdentification of Compound Heterozygous DPM1 Variants in a Pediatric Patient With Congenital Disorder of Glycosylation Type Ie.
Case reports in pediatricsProtein losing enteropathy due to congenital disorder of glycosylation: A case report.
SAGE open medical case reportsNovel SSR4 gene splice variant leads to congenital disorder of glycosylation, type Iy.
Frontiers in pediatricsCongenital disorder of glycosylation type IIb in an infant with developmental and epileptic encephalopathy.
BMJ case reportsNovel PGM1 Mutation in Congenital Disorder of Glycosylation Type 1T: A Case Report of Liver Failure and Myopathy.
The American journal of case reportsOral D-mannose therapy during pregnancy in a woman with MPI-CDG: A case report and management review.
Molecular genetics and metabolismCorrigendum to "Incidence and prevalence of phosphomannomutase 2-congenital disorder of glycosylation: Past, present, and future [Molecular Genetics and Metabolism 146 (2025) 109188]".
Molecular genetics and metabolismTreatment of Single Patient With PMM2-Congenital Disorder of Glycosylation With Govorestat (AT-007), an Aldose Reductase Inhibitor.
JIMD reportsExploring a Circulating miRNA Signature for PMM2-CDG: Initial Insights Toward Diagnosis, Stratification, and Monitoring.
Journal of inherited metabolic diseaseSuspected Central Adrenal Insufficiency in a Patient with Phosphomannomutase 2-Congenital Disorder of Glycosylation.
JCEM case reportsHomozygous PGAP2 Mutation Causes Hyperphosphatasia with Mental Retardation Syndrome-3: Genetic and Clinical Evaluation of the Ultra-Rare Inherited Glycosylphosphatidylinositol Biosynthesis Defect.
Molecular syndromologyImmunopathology in PMM2-CDG: Defective glycosylation impact in the TNFα -TNFR1 signalling pathway.
Frontiers in immunologyDefining the clinical spectrum and genotype-phenotype correlations for CCDC115-CDG: A patient report and review of the literature.
Molecular genetics and metabolismZscan4 as a Candidate Conveyor of Early Developmental Defects in O-GlcNAc Transferase Intellectual Disability.
Molecular & cellular proteomics : MCPAn OGT Missense Variant With Impaired Enzyme Activity in a Child With Severe Developmental Delay and Hepatoblastoma.
American journal of medical genetics. Part ANeuromuscular Defects in a Drosophila Model of the Congenital Disorder of Glycosylation SLC35A2-CDG.
BiomoleculesZebrafish models for congenital disorders of glycosylation (CDG): a systematic review.
Orphanet journal of rare diseasesCongenital Disorder of Glycosylation Following ATP6AP1 Deficiency With Normal Liver Function: A Case Report.
Clinical case reportsMono-allelic p.R37H Dehydrodolichyl Diphosphate Synthase variants lead to protein glycosylation defects, aberrant lipid profiles and interneuron scarcity in a novel mouse model of progressive epileptic encephalopathy.
bioRxiv : the preprint server for biologyInvestigation of the Clinical and Genetic Spectrum of PMM2-CDG: Insights from a Family with a Novel Variant and Previous Studies.
Archives of Iranian medicineBi-Allelic Loss-of-Function Variant in MAN1B1 Cause Rafiq Syndrome and Developmental Delay.
International journal of molecular sciencesActivity values of the enzyme phosphomanomutase 2 for diagnosing the CDG Ia glycosylation defect.
Clinica chimica acta; international journal of clinical chemistryNGLY1-CDDG: report of two cases from India and brief review of literature.
Journal of geneticsPhosphomannomutase 2-congenital disorder of glycosylation: exploring the role of N-glycosylation on the endocrine axes.
Frontiers in endocrinologyIncidence and prevalence of phosphomannomutase 2-congenital disorder of glycosylation: Past, present, and future.
Molecular genetics and metabolismPhenotypic and genotypic description of GMPPA-congenital disorder of glycosylation: A review of 26 cases.
Molecular genetics and metabolismPersistent Neutropenia and Atopy in an Adolescent: A Subtle Presentation of Phosphoglucomutase 3 Deficiency.
CureusA Mild Ataxia-Dominant Phenotype of Phosphomannomutase 2-Congenital Disorder of Glycosylation in a Tunisian Family: Broadening the Geographical Scope.
Journal of movement disordersPGM1 deficiency disrupts sarcomere and mitochondrial function in a stem-cell cardiomyocyte model.
bioRxiv : the preprint server for biologyCongenital Disorder of Glycosylation in a 40-Year-Old Male with Hypogammaglobulinemia.
Clinical chemistryGlycosphingolipid synthesis is impaired in SLC35A2-CDG and improves with galactose supplementation.
Cellular and molecular life sciences : CMLSCase Report: De novo variant of the NUS1 gene associated with developmental delay and autism spectrum disorders in a Chinese family.
Frontiers in pediatricsA recurrent c.953A>C (p. Gln318Pro) variant in ALG11 causing congenital disorder of glycosylation in Turkish population.
NeurogeneticsComplex Metabolomic Changes in a Combined Defect of Glycosylation and Oxidative Phosphorylation in a Patient with Pathogenic Variants in PGM1 and NDUFA13.
CellsTargeted metabolomic evaluation of peripheral blood mononucleated cells from patients with PMM2-CDG.
Scientific reportsThe long way to diagnosis: attention disorder, alcohol addiction or congenital disorder of glycosylation? A case report.
BMC psychiatryBi-allelic UGGT1 variants cause a congenital disorder of glycosylation.
American journal of human geneticsDiagnostic Utility of Next-Generation Sequencing-based CNV Analysis in Eleven Patients with Peters-Plus Syndrome: A Single-Center Experience.
Journal of clinical research in pediatric endocrinologyMannose phosphate isomerase-congenital disorder of glycosylation leads to asymptomatic hypoglycemia.
Molecular genetics and metabolism reportsMannose Phosphate Isomerase Deficiency-Congenital Disorder of Glycosylation (MPI-CDG) Type 1b: Familial Case of Thrombophilia and Liver Disorder.
Clinical chemistryBeneficial effects of Glc-1,6-P2 modulation on mutant phosphomannomutase-2.
Biochimica et biophysica acta. Molecular cell researchAAV-based gene replacement therapy prevents and halts manifestation of abnormal neurological phenotypes in a novel mouse model of PMM2-CDG.
Gene therapyThe Therapeutic Future for Congenital Disorders of Glycosylation.
Journal of inherited metabolic diseaseRecent advances in the clinical spectrum and pathomechanisms associated with X-linked myopathy with excessive autophagy and other VMA21-related disorders.
Journal of neuromuscular diseasesNiemann-Pick C-like Endolysosomal Dysfunction in DHDDS Patient Cells, a Congenital Disorder of Glycosylation, Can Be Treated with Miglustat.
International journal of molecular sciencesCysteine variants in PMM2 lead to protein instability and higher sensitivity to oxidative stress in PMM2-CDG.
International journal of biological macromoleculesC1GALT1C1-Associated Mosaic Disorder of Glycosylation in a Female.
Journal of inherited metabolic diseaseIdentification of CNTN2 as a genetic modifier of PIGA-CDG in a family with incomplete penetrance and in Drosophila.
American journal of human geneticsImprovement of Motor Function in SLC39A8-Related Ataxia Through Manganese Supplementation: A Therapeutic Insight.
Movement disorders clinical practiceRafiq Syndrome: Old Variant in MAN1B1 Gene and Some New Phenotypic Features.
Iranian journal of child neurologyHuman genetic variants in SLC39A8 impact uptake and steady-state metal levels within the cell.
Life science allianceLong-chain acyl-CoA synthetase regulates systemic lipid homeostasis via glycosylation-dependent lipoprotein production.
Life metabolismFirst case report of effective and safe application of cannabidiol to treat concurrent ALG3-CDG and Lennox-Gastaut Syndrome.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyPediatric Anesthetic Management of a Patient With an ALG-13 Gene Mutation, a Rare Congenital Disorder of Glycosylation.
Clinical case reportsProgressive loss of cerebral structures in ALG11-related congenital disorder of glycosylation.
Pediatric neurologyALG8-CDG: advances in molecular and prenatal phenotyping facilitate prenatal diagnosis and genetic counseling.
QJM : monthly journal of the Association of PhysiciansExploiting O-GlcNAc dyshomeostasis to screen O-GlcNAc transferase intellectual disability variants.
Stem cell reportsIntron retention caused by a canonical splicing variant in SSR4-related congenital disorder of glycosylation.
Journal of human geneticsCHIME Syndrome in a Child With Homozygous PIGL p.Leu167Pro Variant.
American journal of medical genetics. Part AO-GlcNAcylation modulates expression and abundance of N-glycosylation machinery in an inherited glycosylation disorder.
Cell reports[Clinical features and genetic analysis of a child with Congenital disorder of glycosylation due to novel variants of COG6 gene].
Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical geneticsThe First Korean Case of MAN1B1-Congenital Disorder of Glycosylation Diagnosed Using Whole-Exome Sequencing and Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry.
Annals of laboratory medicineA drug repurposing screen reveals dopamine signaling as a critical pathway underlying potential therapeutics for the rare disease DPAGT1-CDG.
PLoS geneticsReview and metabolomic profiling of unsolved case reveals newly reported autosomal dominant congenital disorder of glycosylation, type Iw formerly thought to only be an autosomal recessive condition.
Molecular genetics and metabolism reportsNovel insights into antithrombin deficiency enabled by mass spectrometry-based precision diagnostics.
Journal of thrombosis and haemostasis : JTHN-glycoproteomic and proteomic alterations in SRD5A3-deficient fibroblasts.
GlycobiologyCase Report of Friedreich's Ataxia and ALG1 -Related Biochemical Abnormalities in a Patient With Progressive Spastic Paraplegia.
American journal of medical genetics. Part AIdentification of two novel variants in ALG11 causing congenital disorder of glycosylation.
SeizureSensitivity of transferrin isoform analysis for PMM2-CDG.
Molecular genetics and metabolismIdentification of CNTN2 as a genetic modifier of PIGA-CDG through pedigree analysis of a family with incomplete penetrance and functional testing in Drosophila.
bioRxiv : the preprint server for biologyPsychiatric assessment and therapy in an adolescent with ALG6-CDG: a six-month follow-up case report.
European child & adolescent psychiatryNeurodevelopmental profiles of 14 individuals with phosphomannomutase deficiency (PMM2-CDG).
Journal of inherited metabolic diseaseHepG2 PMM2-CDG knockout model: A versatile platform for variant and therapeutic evaluation.
Molecular genetics and metabolismA novel SSR4 variant associated with congenital disorder of glycosylation: a case report and related analysis.
Frontiers in geneticsO-GlcNAc transferase congenital disorder of glycosylation (OGT-CDG): Potential mechanistic targets revealed by evaluating the OGT interactome.
The Journal of biological chemistryIn vitro treatment with liposome-encapsulated Mannose-1-phosphate restores N-glycosylation in PMM2-CDG patient-derived fibroblasts.
Molecular genetics and metabolismMolecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG.
The Journal of biological chemistryInsights into molecular and cellular functions of the Golgi calcium/manganese-proton antiporter TMEM165.
The Journal of biological chemistryCoagulation abnormalities and vascular complications are common in PGM1-CDG.
Molecular genetics and metabolismFrontiers in congenital disorders of glycosylation consortium, a cross-sectional study report at year 5 of 280 individuals in the natural history cohort.
Molecular genetics and metabolismHLH and Recurrent EBV Lymphoma as the presenting manifestation of MAGT1 Deficiency: A Systematic Review of the Expanding Disease Spectrum.
Journal of clinical immunologyGenome and RNA sequencing were essential to reveal cryptic intronic variants associated to defective ATP6AP1 mRNA processing.
Molecular genetics and metabolismDuane syndrome in association with congenital disorder of glycosylation type Ig (ALG12-CDG).
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and StrabismusMutations in the SLC35C1 gene, contributing to significant differences in fucosylation patterns, may underlie the diverse phenotypic manifestations observed in leukocyte adhesion deficiency type II patients.
The international journal of biochemistry & cell biologyNANS-CDG: Expanding clinical insights with a novel patient with novel variants.
American journal of medical genetics. Part AA pseudoautosomal glycosylation disorder prompts the revision of dolichol biosynthesis.
CellSSR4-CDG, an ultra-rare X-linked congenital disorder of glycosylation affecting the TRAP complex: Review of 22 affected individuals including the first adult patient.
Molecular genetics and metabolismCase report: Novel genotype of ALG2-CDG and confirmation of the heptasaccharide glycan (NeuAc-Gal-GlcNAc-Man2-GlcNAc2) as a specific diagnostic biomarker.
Frontiers in geneticsNeuroectoderm phenotypes in a human stem cell model of O-GlcNAc transferase associated with intellectual disability.
Molecular genetics and metabolismDestabilization and Degradation of a Disease-Linked PGM1 Protein Variant.
BiochemistryD-mannose as a new therapy for fucokinase deficiency-related congenital disorder of glycosylation (FCSK-CDG).
Molecular genetics and metabolismLiposome-encapsulated mannose-1-phosphate therapy improves global N-glycosylation in different congenital disorders of glycosylation.
Molecular genetics and metabolismNovel insight into FCSK-congenital disorder of glycosylation through a CRISPR-generated cell model.
Molecular genetics & genomic medicineExpanded prenatal phenotype of ALG12-associated congenital disorder of glycosylation including bilateral multicystic kidneys.
American journal of medical genetics. Part AALG13-Congenital Disorder of Glycosylation (ALG13-CDG): Updated clinical and molecular review and clinical management guidelines.
Molecular genetics and metabolismTranscriptomic analysis identifies dysregulated pathways and therapeutic targets in PMM2-CDG.
Biochimica et biophysica acta. Molecular basis of diseaseDeficient glycan extension and endoplasmic reticulum stresses in ALG3-CDG.
Journal of inherited metabolic diseaseA complement C4-derived glycopeptide is a biomarker for PMM2-CDG.
JCI insightNeurodevelopmental defects in a mouse model of O-GlcNAc transferase intellectual disability.
Disease models & mechanismsTRAPPC11-CDG muscular dystrophy: Review of 54 cases including a novel patient.
Molecular genetics and metabolismPhosphomannomutase 2-congenital disorder of glycosylation presenting with very early onset inflammatory bowel disease.
Indian journal of gastroenterology : official journal of the Indian Society of GastroenterologyPIGN c.776T>C (p.Phe259Ser) variant present in trans with a pathogenic variant for PIGN-congenital disorder of glycosylation: Bella-Noah syndrome.
HeliyonEarly onset epileptic and developmental encephalopathy and MOGS variants: a new diagnosis in the whole exome sequencing (WES) ERA : Report of a new patient and review of the literature.
NeurogeneticsEstablishment of a human induced pluripotent stem cell line(SDQLCHi059-A)from a patient with congenital disorder of glycosylation carrying heterozygous mutation in MPI gene.
Stem cell researchMetabolic etiologies in children with infantile epileptic spasm syndrome: Experience at a tertiary pediatric neurology center.
Brain & developmentExploring ligand interactions with human phosphomannomutases using recombinant bacterial thermal shift assay and biochemical validation.
BiochimieCongenital disorder of glycosylation type Ia in a Chinese family: Function analysis of a novel PMM2 complex heterozygosis mutation.
Molecular genetics and metabolism reportsNeural and metabolic dysregulation in PMM2-deficient human in vitro neural models.
Cell reportsMotor improvement in children with PMM2-CDG syndrome following a six-month rehabilitation treatment utilising whole-body vibration; a retrospective study.
Journal of musculoskeletal & neuronal interactionsSweet ending: When genetics prevent a dramatic CDG diagnostic mistake.
Clinica chimica acta; international journal of clinical chemistryGeneration of human induced pluripotent stem cell line (AOUMEYi001-A) from a patient affected by Congenital disorders of glycosylation (ALG8-CDG) using self-replicating RNA vector.
Stem cell researchInstrumented assessment of gait disturbance in PMM2-CDG adults: a feasibility analysis.
Orphanet journal of rare diseasesUntangling adaptive functioning of PMM2-CDG across age and its impact on parental stress: a cross-sectional study.
Scientific reportsDrosophila models of phosphatidylinositol glycan biosynthesis class A congenital disorder of glycosylation (PIGA-CDG) mirror patient phenotypes.
G3 (Bethesda, Md.)Expanding the phenotype and metabolic basis of ATP6AP2-congenital disorder of glycosylation in a Chinese patient with a novel variant c.185G>A (p.Gly62Glu).
Frontiers in geneticsAdult-onset neurodegeneration in XMEN disease.
Journal of neuroimmunologyCongenital Disorder of Glycosylation in a Child with Macrosomia.
Clinical chemistryDrosophila models of PIGA-CDG mirror patient phenotypes.
bioRxiv : the preprint server for biologyNeurological manifestations in PMM2-congenital disorders of glycosylation (PMM2-CDG): Insights into clinico-radiological characteristics, recommendations for follow-up, and future directions.
Genetics in medicine : official journal of the American College of Medical GeneticsDual effect of tacrolimus on mast cell-mediated allergy and inflammation through Mas-related G protein-coupled receptor X2.
Journal of dermatological sciencePIGO-CDG: A case study with a new genotype, expansion of the phenotype, literature review, and nosological considerations.
JIMD reportsA Case of Congenital Disorder of Glycosylation Type 1b Presenting as Hyperinsulinemic Hypoglycemia and Failure to Thrive.
JCEM case reports"Hide and seek": Misleading transferrin variants in PMM2-CDG complicate diagnostics.
Proteomics. Clinical applicationsQuantitative mapping of the in vivo O-GalNAc glycoproteome in mouse tissues identifies GalNAc-T2 O-glycosites in metabolic disorder.
Proceedings of the National Academy of Sciences of the United States of AmericaIdentification of a muscle-specific isoform of VMA21 as a potent actor in X-linked myopathy with excessive autophagy pathogenesis.
Human molecular geneticsBiallelic missense variants in COG3 cause a congenital disorder of glycosylation with impairment of retrograde vesicular trafficking.
Journal of inherited metabolic diseaseDefining the phenotype of PGAP3-congenital disorder of glycosylation; a review of 65 cases.
Molecular genetics and metabolismInterplay of Impaired Cellular Bioenergetics and Autophagy in PMM2-CDG.
GenesCombined PMM2-CDG and hereditary fructose intolerance in a patient with mild clinical presentation.
Molecular genetics and metabolismCongenital diaphragmatic hernia in siblings with PIGA-related congenital disorder of glycosylation.
American journal of medical genetics. Part AAn oligogenic case of severe neonatal thrombocytopenia and a purportedly benign variant in GFI1B requiring reinterpretation.
PlateletsAssociation between acute complications in PMM2-CDG patients and haemostasis anomalies: Data from a multicentric study and suggestions for acute management.
Molecular genetics and metabolismInborn Errors of Immunity in Children With Invasive Pneumococcal Disease: A Multicenter Prospective Study.
The Pediatric infectious disease journalFisetin alleviates chronic urticaria by inhibiting mast cell activation via MRGPRX2.
The Journal of pharmacy and pharmacologyActivation of ryanodine-sensitive calcium store drives pseudo-allergic dermatitis via Mas-related G protein-coupled receptor X2 in mast cells.
Frontiers in immunologyMetabolic adaptation of human skin fibroblasts to ER stress caused by glycosylation defect in PMM2-CDG.
Molecular genetics and metabolismOral sialic acid supplementation in NANS-CDG: Results of a single center, open-label, observational pilot study.
Journal of inherited metabolic diseaseAn O-GlcNAc transferase pathogenic variant linked to intellectual disability affects pluripotent stem cell self-renewal.
Disease models & mechanismsD-galactose Supplementation for the Treatment of Mild Malformation of Cortical Development with Oligodendroglial Hyperplasia in Epilepsy (MOGHE): A Pilot Trial of Precision Medicine After Epilepsy Surgery.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeuticsPMM2 -CDG T237M Mutation in a Patient with Cerebral Palsy-Like Phenotypes Reported from South India.
Global medical geneticsA liposomal carbohydrate vaccine, adjuvanted with an NKT cell agonist, induces rapid and enhanced immune responses and antibody class switching.
Journal of nanobiotechnologyTracer metabolomics reveals the role of aldose reductase in glycosylation.
Cell reports. MedicineNovel NUS1 variant in a Chinese patient with progressive myoclonus epilepsy: a case report and systematic review.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyComplex metabolic disharmony in PMM2-CDG paves the way to new therapeutic approaches.
Molecular genetics and metabolismSubstance P analogs devoid of key residues fail to activate human mast cells via MRGPRX2.
Frontiers in immunologyCoagulation abnormalities in a prospective cohort of 50 patients with PMM2-congenital disorder of glycosylation.
Molecular genetics and metabolismMAGT1 deficiency in XMEN disease is associated with severe platelet dysfunction and impaired platelet glycoprotein N-glycosylation.
Journal of thrombosis and haemostasis : JTHA novel variant in ALG1 gene associated with congenital disorder of glycosylation: A case report and short literature review.
Molecular genetics & genomic medicineNovel insights into the phenotype and long-term D-gal treatment in PGM1-CDG: a case series.
Therapeutic advances in rare diseaseMannose treatment improves immune deficiency in mannose phosphate isomerase-congenital disorder of glycosylation: case report and review of literature.
Therapeutic advances in rare diseaseCongenital disorder of glycosylation - one size does not fit all: a parent's perspective.
Therapeutic advances in rare diseaseIn Vitro Skeletal Muscle Model of PGM1 Deficiency Reveals Altered Energy Homeostasis.
International journal of molecular sciencesMannose phosphate isomerase gene mutation leads to a congenital disorder of glycosylation: A rare case report and literature review.
Frontiers in pediatricsClinical Presentation of a Patient with a Congenital Disorder of Glycosylation, Type IIs (ATP6AP1), and Liver Transplantation.
International journal of molecular sciencesA Rare Case of Cerebrotendinous Xanthomatosis Associated With a Mutation on COG8 Gene.
Journal of investigative medicine high impact case reportsAbnormal expression of lysosomal glycoproteins in patients with congenital disorders of glycosylation.
BMC research notesThe epilepsy phenotype of ST3GAL3-related developmental and epileptic encephalopathy.
Epilepsia openThe First Congenital Disorders of Glycosylation Patient (Fetus) with Homozygous COG5 c.95T>G Variant.
Molecular syndromologyLiver transplantation recovers hepatic N-glycosylation with persistent IgG glycosylation abnormalities: Three-year follow-up in a patient with phosphomannomutase-2-congenital disorder of glycosylation.
Molecular genetics and metabolismMyricetin served as antagonist for negatively regulate MRGPRX2 mediated pseudo-allergic reactions through CD300f/SHP1/SHP2 phosphorylation.
International immunopharmacologyMirror Movements and Dystonia in SRD5A3-Related Congenital Disorders of Glycosylation: Expanding the Phenotypic and Genotypic Spectrum.
Movement disorders clinical practiceMast Cell Proteases Cleave Prion Proteins and a Recombinant Ig against PrP Can Activate Human Mast Cells.
Journal of immunology (Baltimore, Md. : 1950)Long-term outcomes in ALG13-Congenital Disorder of Glycosylation.
American journal of medical genetics. Part A[Advances in the diagnosis and treatment of phosphomannomutase 2 deficiency].
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics[A case of Congenital disorder of glycosylation due to SSR4 gene deletion].
Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical geneticsPhosphomannomutase 2 (PMM2) variants leading to hyperinsulinism-polycystic kidney disease are associated with early-onset inflammatory bowel disease and gastric antral foveolar hyperplasia.
Human geneticsA Case of ALG6-CDG with Explosive Onset of Intractable Epilepsy During Infancy.
Child neurology openCysteine Pathogenic Variants of PMM2 Are Sensitive to Environmental Stress with Loss of Structural Stability.
Oxidative medicine and cellular longevityPhosphomannomutase 2 hyperinsulinemia: Recent advances of genetic pathogenesis, diagnosis, and management.
Frontiers in endocrinologyRhinovirus infection of the airway epithelium enhances mast cell immune responses via epithelial-derived interferons.
The Journal of allergy and clinical immunologyMannose: a potential saccharide candidate in disease management.
Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agentsNeurological insights on two siblings with GM3 synthase deficiency due to novel compound heterozygous ST3GAL5 variants.
Brain & developmentFractionated plasma N-glycan profiling of novel cohort of ATP6AP1-CDG subjects identifies phenotypic association.
Journal of inherited metabolic diseaseEsomeprazole induces structural changes and apoptosis and alters function of in vitro canine neoplastic mast cells.
Veterinary immunology and immunopathologyCase report: The art of anesthesiology-Approaching a minor procedure in a child with MPI-CDG.
Frontiers in pharmacologyWhole exome sequencing reveals several novel variants in congenital disorders of glycosylation and glycogen storage diseases in seven patients from Iran.
Molecular genetics & genomic medicineA rare case of SRD5A3-CDG in a patient with ataxia and telangiectasia: A case report.
Clinical case reportsCongenital disorder of glycosylation with defective fucosylation 2 (FCSK gene defect): The third report in the literature with a mild phenotype.
Molecular genetics & genomic medicineHyperinsulinemic Hypoglycemia Due to PMM2 Mutation in Two Siblings with Autosomal Recessive Polycystic Kidney Disease.
Pediatric reportsAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Doença congênita da glicosilação.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Doença congênita da glicosilação e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
A doença é causada por alterações genéticas que prejudicam a atividade das enzimas responsáveis pelo processo de glicosilação celular. Ela pode ser herdada de forma autossômica recessiva ou recessiva ligada ao cromossomo X, envolvendo genes como PGM1, FCSK e FUT8.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
10 publicações do grafo RarasNet (PubMed) · 6 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (s.d.). Doença congênita da glicosilação. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/doenca-congenita-da-glicosilacao
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Doença congênita da glicosilação
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- Codificação WHO/SUS
- fonte: WHO ICD-10 / DATASUS
- NIH/GARD
- fonte: GARD (NIH)
- Indexação biomédica
- fonte: MeSH (NLM)
- Dado público estruturado
- fonte: Wikidata
- Moléculas estudadas na doença
- fonte: OpenTargets
- Ensaios clínicos
- fonte: ClinicalTrials.gov